Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Zhaolin Xu"'
Autor:
Gopal P. Pathak, Rashmi Shah, Mathieu Castonguay, Angela Cheng, John Fris, Rowan Murphy, Gail Darling, Alexander Ednie, Daniel French, Harry Henteleff, Aneil Mujoomdar, Madelaine Plourde, Alison Wallace, Zhaolin Xu
Publikováno v:
Cancer Medicine, Vol 13, Iss 19, Pp n/a-n/a (2024)
ABSTRACT Objectives Several studies rely on archived tissue blocks to assess the PD‐L1 scores; however, a detailed analysis of potential variations of scores between fresh and archived tissue blocks still lacks. In addition, the prognostic implicat
Externí odkaz:
https://doaj.org/article/ff5a5695ce2448108b9d6431f5d82b1b
Publikováno v:
Vaccines, Vol 12, Iss 6, p 577 (2024)
Toxoplasmosis is a significant global zoonosis with devastating impacts, and an effective vaccine against toxoplasmosis for humans has not yet been developed. In this study, we designed and formulated a novel DNA vaccine encoding the inhibitor of STA
Externí odkaz:
https://doaj.org/article/a6a1d75b926b46358c71657ea0964383
Publikováno v:
地质科技通报, Vol 41, Iss 4, Pp 30-37 (2022)
Because of the Klinkenberge effect in tight sandstones, errors exist forusing air permeability to reflect its reality, and it is thus important to determine the absolute permeability of tight sandstone.The Gaussian process regression (GPR), a state-o
Externí odkaz:
https://doaj.org/article/b894ba4a71b043a38809cb97665ca4e8
Autor:
Diana N. Ionescu, Tracy L. Stockley, Shantanu Banerji, Christian Couture, Cheryl A. Mather, Zhaolin Xu, Normand Blais, Parneet K. Cheema, Quincy S.-C. Chu, Barbara Melosky, Natasha B. Leighl
Publikováno v:
Current Oncology, Vol 29, Iss 7, Pp 4981-4997 (2022)
Non-small cell lung cancer (NSCLC) has historically been associated with a poor prognosis and low 5-year survival, but the use of targeted therapies in NSCLC has improved patient outcomes over the past 10 years. The pace of development of new targete
Externí odkaz:
https://doaj.org/article/1ed9d430c59d4d3496913a7bcdcbbc84
Publikováno v:
npj Genomic Medicine, Vol 6, Iss 1, Pp 1-15 (2021)
Abstract Lung cancer accounts for more than half of the new cancers diagnosed world-wide with poor survival rates. Despite the development of chemical, radiological, and immunotherapies, many patients do not benefit from these therapies, as recurrenc
Externí odkaz:
https://doaj.org/article/ff3e24a74317479a8916e37c8e48330f
Autor:
Nada Ismaiel, Sara Whynot, Laurette Geldenhuys, Zhaolin Xu, Arthur S. Slutsky, Valerie Chappe, Dietrich Henzler
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
Background and Objective: Lung-protective mechanical ventilation is known to attenuate ventilator-associated lung injury (VALI), but often at the expense of hypoventilation and hypercapnia. It remains unclear whether the main mechanism by which VALI
Externí odkaz:
https://doaj.org/article/08a8829ca1b14494880f95b18d491ad6
Autor:
Katey S. S. Enfield, Erin A. Marshall, Christine Anderson, Kevin W. Ng, Sara Rahmati, Zhaolin Xu, Megan Fuller, Katy Milne, Daniel Lu, Rocky Shi, David A. Rowbotham, Daiana D. Becker-Santos, Fraser D. Johnson, John C. English, Calum E. MacAulay, Stephen Lam, William W. Lockwood, Raj Chari, Aly Karsan, Igor Jurisica, Wan L. Lam
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Tissue context can dictate why a gene can have seemingly opposing functions in different settings. ELF3 is tumor suppressive in many cancers of epithelial origin but in lung cancer, the authors describe an oncogenic role in the adenocarcinoma histolo
Externí odkaz:
https://doaj.org/article/97564470fd144a769823f07282f004b8
Autor:
Dietrich Henzler, Alf Schmidt, Zhaolin Xu, Nada Ismaiel, Haibo Zhang, Arthur S. Slutsky, Paolo Pelosi
Publikováno v:
Intensive Care Medicine Experimental, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background An on-going debate exists as to whether partial ventilatory support is lung protective in an acute phase of ARDS. So far, the effects of different respiratory efforts on the development of ventilator-associated lung injury (VALI)
Externí odkaz:
https://doaj.org/article/8515d5a2e21f48e0a5510d103364b850
Autor:
Akram Alwithenani, Drew Bethune, Mathieu Castonguay, Arik Drucker, Gordon Flowerdew, Marika Forsythe, Daniel French, John Fris, Wenda Greer, Harry Henteleff, Mary MacNeil, Paola Marignani, Wojciech Morzycki, Madelaine Plourde, Stephanie Snow, Paola Marcato, Zhaolin Xu
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0251080 (2021)
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with very low response rate. Lung cancer is the most common cause of cancer death worldwide. Therapies that target driver gene mutations (e.g. EGFR, ALK, R
Externí odkaz:
https://doaj.org/article/e3c4b71be1604259a8c3660958c74ff8
Autor:
Marika L Forsythe, Akram Alwithenani, Drew Bethune, Mathieu Castonguay, Arik Drucker, Gordon Flowerdew, Daniel French, John Fris, Wenda Greer, Harry Henteleff, Mary MacNeil, Paola Marignani, Wojciech Morzycki, Madelaine Plourde, Stephanie Snow, Zhaolin Xu
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0236580 (2020)
Lung cancer is generally treated with conventional therapies, including chemotherapy and radiation. These methods, however, are not specific to cancer cells and instead attack every cell present, including normal cells. Personalized therapies provide
Externí odkaz:
https://doaj.org/article/d358aab1202849d2b0953d9c467d7576